Interplay between pro-inflammatory cytokines and chromatin-remodeling enzymes in the regulation of central nervous system demyelination and repair

A03

Our work suggests that modulating the activity of the enzyme HDAC1/2 could have multiple beneficial effects in the context of MS by decreasing demyelination induced by interleukin (IL-)17 and tumor necrosis factor (TNF), as well as by enhancing the remyelination of lesions. Here we want to study the role of HDAC1/2 and IL-17/TNF signaling and their interplay on myelination and remyelination of the CNS in the context of inflammation. To do so, we will use genetic mouse models as well as human induced pluripotent stem cells (iPSC)-derived neural cells. These are our research questions::

    1. How do IL-17 and TNF signaling in oligodendrocytes and their precursors dictate the process of de- and remyelination?
    2. How do HDAC1/2 influence demyelination in the context of EAE?
    3. How do HDAC1/2 interact with IL-17 signaling?
    4. Can pharmacological activators of HDAC2 be used as a treatment for multiple sclerosis? To elucidate this question, we will use human cells cultured in a microfluidic model of myelination.

 

 

 

 

 

 

 

 

Principal Investigators:

Univ.-Prof. Dr. rer. nat. Ari Waisman
Institut für Molekulare Medizin
Mainz
waisman@uni-mainz.de

Prof. Dr. rer. nat. Claire Jacob
Institut für Entwicklungsbiologie und Neurobiologie
Mainz
cjacob@uni-mainz.de

News

Mon, 20/09/2021
Register now: 1st Symposium inflammation and imaging
When?: from November 2nd to November 4th 2021 Where?: Schloss (seat of the University Administration) Muenster Organizers: Co-operative Research Centres 1009, 1450, Transregio 128, and Clinical Research Unit 342 – together with Interdisciplinary Centre of Clinical Research (IZKF) and Excellence Cluster Cells in Motion (CiM) Registration is open now! More information: here...more
Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more